Repare Therapeutics (RPTX) Company Overview

Repare Therapeutics (RPTX) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term.

CAMBRIDGE, Mass. & MONTREAL--(BUSINESS WIRE)--Repare Therapeutics Announces Positive Results of the Lunresertib and Camonsertib Combination from the MYTHIC Ph1 Gynecologic Expansion Clinical Trial.

CAMBRIDGE, Mass. & MONTREAL--(BUSINESS WIRE)--Repare Therapeutics to Host Webcast to Report Data from the Lunresertib and Camonsertib Combination Phase 1 MYTHIC Clinical Trial.

CAMBRIDGE, Mass. & MONTREAL--(BUSINESS WIRE)--Repare Therapeutics Announces Updated Positive Safety and Tolerability Results from the Phase 1 MYTHIC Clinical Trial.

CAMBRIDGE, Mass. & MONTREAL--(BUSINESS WIRE)--Repare Therapeutics Doses First Patient in Phase 1 Clinical Trial of RP-3467, a Polθ ATPase Inhibitor.

Repare Therapeutics Inc. results from phase 1 MYTHIC study, using lunresertib + camonsertib for the treatment of platinum-resistant ovarian and endometrial cancer with genomic alterations, are expected in Q4 of 2024. Preliminary RECIST response data from 10 patients using the lunresertib + camonsertib combination for ovarian and endometrial cancer patients was 50%. The global ovarian cancer market is expected to reach $11.18 billion by 2029.

CAMBRIDGE, Mass. & MONTREAL--(BUSINESS WIRE)--Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), a leading clinical-stage precision oncology company, today announced the first patient has been dosed in the Company's camonsertib monotherapy non-small cell lung cancer (NSCLC) expansion of the TRESR clinical trial. “Camonsertib has demonstrated a promising signal of prolonged progression free survival in patients with ATM-mutated NSCLC in our ongoing TRESR clinical trial. We are.

Repare (RPTX) rises 14% as the FDA grants Fast Track designation to its investigational lunresertib/camonsertib combo to treat adult ovarian cancer patients in the United States.

CAMBRIDGE, Mass. & MONTREAL--(BUSINESS WIRE)--Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), a leading clinical-stage precision oncology company, announced initial data from the Phase 1 MINOTAUR study evaluating lunresertib (RP-6306) in combination with FOLFIRI for the treatment of advanced solid tumors has been selected for a poster presentation at the European Society of Medical Oncology (ESMO) Gastrointestinal (GI) Cancers Congress 2024, being held June 26-29 in Munich,.